BACKGROUND: The convergence of nutritional, genetic, and inflammatory factors plays a significant role in the pathophysiology of squamous cell esophageal cancer (SCEC). The parameters of inflammation, indices of nutritional status, and adipocyte-derived hormones such as leptin, adiponectin, and resistin have been shown to be prognostic factors in some gastrointestinal and pancreatic cancers. MATERIAL/METHODS: Forty-two patients with SCEC were subjected to a multimodal regimen of concurrent neoadjuvant chemoradiotherapy (CRT) followed by surgery. We retrospectively analyzed the impact of pretreatment values of serum leptin, adiponectin, resistin, soluble leptin receptor, C-reactive protein, TNF alpha, leukocytes, and indices of nutritional status (BMI, plasma total protein, albumin, cholesterol, and triacylglycerols) on overall survival (OS). RESULTS: Univariate analysis revealed significant a negative correlation between OS and serum adiponectin (p=0.027), and a positive relationship was found between serum albumin (p=0.002), cholesterol (p=0.049) level, and OS. In multivariate analysis, only the trend (p=0.086) for negative serum adiponectin association with the OS was observed. CONCLUSIONS: In men with SCEC treated by neoadjuvant concurrent CRT and esophagectomy, high pretreatment level of serum adiponectin was associated with shorter OS while the serum albumin and cholesterol were associated with longer OS.

3rd Clinic of Surgery 1st Faculty of Medicine of Charles University Prague and General University Hospital Prague Czech Republic

4rd Department of Internal Medicine 1st Faculty of Medicine of Charles University Prague and General University Hospital Prague Czech Republic

4th Department of Internal Medicine 1st Faculty of Medicine of Charles University Prague and General University Hospital Prague Czech Republic

Clinic of Oncology 1st Faculty of Medicine of Charles University Prague and General University Hospital Prague Czech Republic

Zobrazit více v PubMed

Coleman MP, Gatta G, Verdecchia A, et al. EUROCARE-3 summary: cancer survival in Europe at the end of the 20th century. Ann Oncol. 2003;14(Suppl 5):128–49. PubMed

ÚZIS ČR. Novotvary 2010. Prague: ÚZIS; 2013. [in Czech]

Gebski V, Burmeister B, Smithers BM, et al. Australasian Gastro-Intestinal Trials Group: Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol. 2007;8:226–34. PubMed

Riley RD, Sauerbrei W, Altman DG. Prognostic markers in cancer: the evolution of evidence from single studies to meta-analysis, and beyond. Br J Cancer. 2009;100:1219–29. PubMed PMC

Fang Y, Fang D, Hu J. MicroRNA and its roles in esophageal cancer. Med Sci Monit. 2011;17(5):CR248–58. PubMed PMC

Pohl H, Wrobel K, Bojarski C, et al. Risk factors in the development of esophageal adenocarcinoma. Am J Gastroenterol. 2013;108:200–7. PubMed

Rodriguez-Vita J, Lawrence T. The resolution of inflammation and cancer. Cytokine Growth Factor Rev. 2010;21:61–65. PubMed

Krechler T, Jáchymová M, Pavliková M, et al. Polymorphism -23HPhI in the promoter of insulin gene and pancreatic cancer: a pilot study. Neoplasma. 2009;56:26–32. PubMed

Tetreault MP, Wang ML, Yang Y, et al. Klf4 overexpression activates epithelial cytokines and inflammation-mediated esophageal squamous cell cancer in mice. Gastroenterology. 2010;139:2124–34.e9. PubMed PMC

McMillan DC, Canna K, McArdle CS. Systemic inflammatory response predicts survival following curative resection of colorectal cancer. Br J Surg. 2003;90:215–19. PubMed

Gupta D, Lis CG. Pretreatment serum albumin as a predictor of cancer survival: A systematic review of the epidemiological literature. Nutr J. 2010;9:69. PubMed PMC

Nakajima TE, Yamada Y, Hamano T, et al. Adipocytokines as new promising markers of colorectal tumors: adiponectin for colorectal adenoma, and resistin and visfatin for colorectal cancer. Cancer Sci. 2010;101:1286–91. PubMed PMC

Paz-Filho G, Lim EL, Wong ML, Licinio J. Associations between adipokines and obesity-related cancer. Front Biosci. 2011;16:1634–50. PubMed

Mantzoros CS, Magkos F, Brinkoetter M, et al. Leptin in human physiology and pathophysiology. Am J Physiol Endocrinol Metab. 2011;301:E567–84. PubMed PMC

Ge H, Huang L, Pourbahrami T, Li C. Generation of soluble leptin receptor by ectodomain shedding of membrane-spanning receptors in vitro and in vivo. J Biol Chem. 2002;277:45898–903. PubMed

Garofalo C, Surmacz E. Leptin and cancer. J Cell Physiol. 2006;207:12–22. PubMed

Arpaci F, Yilmaz MI, Ozet A, et al. Low serum leptin level in colon cancer patients without significant weight loss. Tumori. 2002;88:147–49. PubMed

Krechler T, Zeman M, Vecka M, et al. Leptin and adiponectin in pancreatic cancer: connection with diabetes mellitus. Neoplasma. 2011;58:58–64. PubMed

Stachowicz M, Mazurek U, Nowakowska-Zajdel E, et al. Leptin and its receptors in obese patients with colorectal cancer. J Biol Regul Homeost Agents. 2010;24:287–95. PubMed

Tutino V, Notarnicola M, Guerra V, et al. Increased soluble leptin receptor levels are associated with advanced tumor stage in colorectal cancer patients. Anticancer Res. 2011;31:3381–83. PubMed

Beltowski J. Adiponectin and resistin – new hormones of white adipose tissue. Med Sci Monit. 2003;9(2):RA55–61. PubMed

Kadowaki T, Yamauchi T, Kubota N. The physiological and pathophysiological role of adiponectin and adiponectin receptors in the peripheral tissues and CNS. FEBS Lett. 2008;582:74–80. PubMed

Barb D, Williams CJ, Neuwirth AK, Mantzoros CS. Adiponectin in relation to malignancies: a review of existing basic research and clinical evidence. Am J Clin Nutr. 2007;86(Suppl):858S–66S. PubMed

Ahima RS, Lazar MA. Adipokines and the peripheral and neural control of energy balance. Mol Endocrinol. 2008;22:1023–31. PubMed PMC

Patel L, Buckels AC, Kinghorn IJ, et al. Resistin is expressed in human macrophages and directly regulated by PPAR-activators. Biochem Biophys Res Commun. 2003;300:472. PubMed

Sun CA, Wu MH, Chu CH, et al. Adipocytokine resistin and breast cancer risk. Breast Cancer Res Treat. 2010;123:869–76. PubMed

Hlavna M, Kohut L, Lipkova J, et al. Relationship of resistin levels with endometrial cancer risk. Neoplasma. 2011;58:124–28. PubMed

Karapanagiotou EM, Tsochatzis EA, Dilana KD, et al. The significance of leptin, adiponectin, and resistin serum levels in non-small cell lung cancer (NSCLC) Lung Cancer. 2008;61:391–97. PubMed

Danese E, Montagnana M, Minicozzi A, et al. The role of resistin in colorectal cancer. Clin Chim Acta. 2012;413:760–64. PubMed

Dalamaga M, Karmaniolas K, Panagiotou A, et al. Low circulating adiponectin and resistin, but not leptin, levels are associated with multiple myeloma risk: a case-control study. Cancer Causes Control. 2009;20:193–99. PubMed

Nakajima TE, Yamada Y, Hamano T, et al. Adipocytokines and squamous cell carcinoma of the esophagus. J Cancer Res Clin Oncol. 2010;136:261–66. PubMed

Sobin LH, Wittekind C, editors. TNM Classification of Malignant Tumors, fifth edition, UICC – International Union Against Cancer. Wiley-Liss; 1997. PubMed

Czech version, Prague. 2000. pp. 52–55.

Zemanová M, Petruželka L, Pazdro A, et al. Prospective non-randomized study of preoperative concurrent platinum plus 5fluorouracil-based chemoradiotherapy with or without paclitaxel in esophageal cancer patients: long-term follow-up. Dis Esophagus. 2010;23:160–67. PubMed

Mariette C, De Botton ML, Piessen G. Surgery in esophageal and gastric cancer patients: what is the role for nutrition support in your daily practice? Ann Surg Oncol. 2012;19:2128–34. PubMed

Zemanová M, Novák F, Vitek P, et al. Outcomes of patients with oesophageal cancer treated with preoperative chemoradiotherapy, followed by tumor resection: influence of nutritional factors. J BUON. 2012;17:310–16. PubMed

Beberashvili I, Sinuani I, Azar A, et al. IL-6 levels, nutritional status, and mortality in prevalent hemodialysis patients. Clin J Am Soc Nephrol. 2011;6:2253–63. PubMed PMC

Cincibuch J, Neoral C, Aujeský R, et al. Prognostic factors in patients with esophageal carcinoma treated with chemoradiation: single center experience. Hepatogastroenterology. 2010;57:1145–49. PubMed

Sok M, Ravnik J, Ravnik M. Preoperative total serum cholesterol as a prognostic factor for survival in patients with resectable non-small-cell lung cancer. Wien Klin Wochenschr. 2009;121:314–17. PubMed

Erlinger TP, Muntner P, Helzlsouer KJ. WBC count and the risk of cancer mortality in a national sample of U.S. adults: results from the Second National Health and Nutrition Examination Survey mortality study. Cancer Epidemiol Biomarkers Prev. 2004;13:1052–56. PubMed

Lee YJ, Lee HR, Nam CM, Hwang UK, Jee SH. White blood cell count and the risk of colon cancer. Yonsei Med J. 2006;47:646–56. PubMed PMC

Li H, Stampfer MJ, Mucci L, et al. A 25-year prospective study of plasma adiponectin and leptin concentrations and prostate cancer risk and survival. Clin Chem. 2010;56:34–43. PubMed PMC

Otake S, Takeda H, Fujishima S, et al. Decreased levels of plasma adiponectin associated with increased risk of colorectal cancer. World J Gastroenterol. 2010;16:1252–57. PubMed PMC

Ishikawa M, Kitayama J, Kazama S, et al. Plasma adiponectin and gastric cancer. Clin Cancer Res. 2005;11:466–72. PubMed

Vona-Davis L, Rose DP. Adipokines as endocrine, paracrine, and autocrine factors in breast cancer risk and progression. Endocr Relat Cancer. 2007;14:189–206. PubMed

Yildirim A, Bilici M, Cayir K, et al. Serum Adiponectin Levels in Patients with Esophageal Cancer. Jpn J Clin Oncol. 2009;39:92–96. PubMed

Diao Y, Li H, Li H, et al. Association of serum levels of lipid and its novel constituents with the different stages of esophageal carcinoma. Lipids Health Dis. 2009;8:48. PubMed PMC

Petridou ET, Sergentanis TN, Dessypris N, et al. Serum adiponectin as a predictor of childhood non-Hodgkin’s lymphoma: a nationwide case-control study. J Clin Oncol. 2009;27:5049–55. PubMed PMC

Dalamaga M, Migdalis I, Fargnoli JL, et al. Pancreatic cancer expresses adiponectin receptors and is associated with hypoleptinemia and hyperadiponectinemia: a case-control study. Cancer Causes Control. 2009;20:625–33. PubMed PMC

Nowosielski K, Pozowski J, Ulman-Włodarz I, et al. Adiponectin to leptin index as a marker of endometrial cancer in postmenopausal women with abnormal vaginal bleeding: an observational study. Neuro Endocrinol Lett. 2012;33:217–23. PubMed

Wolf I, Sadetzki S, Kanety H, et al. Adiponectin, ghrelin, and leptin in cancer cachexia in breast and colon cancer patients. Cancer. 2006;106:966–73. PubMed

Leth H, Andersen KK, Frystyk J, et al. Elevated levels of high-molecular-weight adiponectin in type 1 diabetes. J Clin Endocrinol Metab. 2008;93:3186–91. PubMed

Fantuzzi G. Adiponectin and inflammation: consensus and controversy. J Allergy Clin Immunol. 2008;121:326–30. PubMed

Faraj M, Havel PJ, Phelis S, et al. Plasma acylation-stimulating protein, adiponectin, leptin, and ghrelin before and after weight loss induced by gastric bypass surgery in morbidly obese subjects. J Clin Endocrinol Metab. 2003;88:1594–602. PubMed

Kim HJ, Kim HJ, Yun J, et al. Pathophysiological role of hormones and cytokines in cancer cachexia. J Korean Med Sci. 2012;27:128–34. PubMed PMC

Plasma Phosphatidylcholines Fatty Acids in Men with Squamous Cell Esophageal Cancer: Chemoradiotherapy Improves Abnormal Profile